Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
APGE Apogee Therapeutics	$39.31 +0.8%	$40.37	$26.20 ▼ $63.50	$1.81B	1.47	612,198 shs	824,624 shs
BHC Bausch Health Cos	$6.31 -2.6%	$5.57	$3.96 ▼ $9.85	$2.34B	0.41	2.54 million shs	902,877 shs
GLPG Galapagos	$31.14 +1.6%	$28.44	$22.36 ▼ $31.39	$2.05B	0.07	255,940 shs	306,541 shs
ZVRA Zevra Therapeutics	$12.07 -4.7%	$9.45	$5.45 ▼ $13.16	$659.99M	1.97	736,126 shs	1.20 million shs

The Next 7 Blockbuster Stocks for Growth Investors

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
APGE Apogee Therapeutics	+1.64%	+1.11%	-6.39%	+17.79%	-20.75%
BHC Bausch Health Cos	+0.68%	-2.41%	+13.14%	+26.54%	-14.90%
GLPG Galapagos	+1.36%	+0.56%	+9.81%	+24.33%	+13.56%
ZVRA Zevra Therapeutics	+2.76%	+5.32%	+43.70%	+77.06%	+92.11%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
APGE Apogee Therapeutics	3.0043 of 5 stars	3.5	3.0	0.0	2.1	4.2	0.0
BHC Bausch Health Cos	3.7238 of 5 stars	1.9	4.0	4.0	1.8	3.3	0.6
GLPG Galapagos	0.5928 of 5 stars	0.8	4.0	0.0	2.7	0.0	0.6
ZVRA Zevra Therapeutics	3.1134 of 5 stars	3.6	5.0	0.0	3.3	0.0	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
APGE Apogee Therapeutics	3.00	Buy	$99.00	151.84% Upside
BHC Bausch Health Cos	1.83	Reduce	$7.30	15.69% Upside
GLPG Galapagos	1.50	Reduce	$25.33	-18.65% Downside
ZVRA Zevra Therapeutics	3.11	Buy	$23.71	96.47% Upside

Current Analyst Ratings Breakdown

Latest ZVRA, APGE, GLPG, and BHC Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/10/2025	ZVRA Zevra Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$25.00 ➝ $29.00
7/7/2025	APGE Apogee Therapeutics	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
7/7/2025	APGE Apogee Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$90.00
7/7/2025	APGE Apogee Therapeutics	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$100.00 ➝ $115.00
7/2/2025	APGE Apogee Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$116.00
7/2/2025	ZVRA Zevra Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$26.00
5/14/2025	ZVRA Zevra Therapeutics	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform
5/14/2025	ZVRA Zevra Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$25.00 ➝ $25.00
5/2/2025	BHC Bausch Health Cos	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Sector Perform ➝ Sector Perform	$8.50 ➝ $10.00

(Data available from 7/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
APGE Apogee Therapeutics	N/A	N/A	N/A	N/A	$15.92 per share	N/A
BHC Bausch Health Cos	$9.63B	0.24	$7.60 per share	0.83	($0.89) per share	-7.09
GLPG Galapagos	$288.19M	7.12	$0.75 per share	41.66	$47.57 per share	0.65
ZVRA Zevra Therapeutics	$23.61M	27.95	N/A	N/A	$0.74 per share	16.31

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
APGE Apogee Therapeutics	-$182.15M	-$3.60	N/A	N/A	N/A	N/A	-28.35%	-26.98%	8/11/2025 (Estimated)
BHC Bausch Health Cos	-$46M	-$0.11	N/A	1.35	N/A	-0.41%	-540.45%	5.26%	7/30/2025 (Estimated)
GLPG Galapagos	$80.16M	N/A	0.00	N/A	N/A	N/A	N/A	N/A	7/23/2025 (Estimated)
ZVRA Zevra Therapeutics	-$105.51M	-$1.90	N/A	60.35	N/A	-226.78%	-201.05%	-53.55%	8/12/2025 (Estimated)

Latest ZVRA, APGE, GLPG, and BHC Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2025	Q2 2025	ZVRA Zevra Therapeutics	$0.65	N/A	N/A	N/A	$22.49 million	N/A
8/11/2025	Q2 2025	APGE Apogee Therapeutics	-$1.08	N/A	N/A	N/A	N/A	N/A
7/30/2025	Q2 2025	BHC Bausch Health Cos	$0.9320	N/A	N/A	N/A	$2.47 billion	N/A
7/23/2025	Q2 2025	GLPG Galapagos	-$0.34	N/A	N/A	N/A	$80.13 million	N/A
5/13/2025	Q1 2025	ZVRA Zevra Therapeutics	-$0.21	-$0.06	+$0.15	-$0.06	$16.96 million	$20.40 million
5/12/2025	Q1 2025	APGE Apogee Therapeutics	-$1.19	-$0.95	+$0.24	-$0.95	N/A	N/A
4/23/2025	Q1 2025	GLPG Galapagos	-$0.23	-$2.47	-$2.24	-$2.45	$72.22 million	$97.33 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
APGE Apogee Therapeutics	N/A	N/A	N/A	N/A	N/A
BHC Bausch Health Cos	N/A	N/A	N/A	N/A	N/A
GLPG Galapagos	N/A	N/A	N/A	N/A	N/A
ZVRA Zevra Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
APGE Apogee Therapeutics	N/A	15.82	15.82
BHC Bausch Health Cos	N/A	1.35	0.97
GLPG Galapagos	N/A	7.95	7.86
ZVRA Zevra Therapeutics	1.46	3.02	2.93

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
APGE Apogee Therapeutics	79.04%
BHC Bausch Health Cos	78.65%
GLPG Galapagos	32.46%
ZVRA Zevra Therapeutics	35.03%

Insider Ownership

Company	Insider Ownership
APGE Apogee Therapeutics	42.77%
BHC Bausch Health Cos	8.05%
GLPG Galapagos	2.91%
ZVRA Zevra Therapeutics	2.40%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
APGE Apogee Therapeutics	91	46.05 million	26.35 million	Optionable
BHC Bausch Health Cos	20,700	370.08 million	340.29 million	Optionable
GLPG Galapagos	1,310	65.90 million	N/A	Optionable
ZVRA Zevra Therapeutics	20	54.68 million	53.37 million	Optionable

ZVRA, APGE, GLPG, and BHC Headlines

Recent News About These Companies

Zevra Therapeutics Announces MIPLYFFA® and OLPRUVA® Presentations at the Annual Meeting of the Southeastern Regional Genetics Group (SERGG)

July 18 at 7:30 AM | globenewswire.com

Q2 EPS Forecast for Zevra Therapeutics Boosted by Analyst

July 18 at 2:13 AM | americanbankingnews.com

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Shares Acquired by Mystic Asset Management Inc.

July 17 at 9:39 AM | marketbeat.com

William Blair Issues Optimistic Forecast for ZVRA Earnings

July 17 at 2:25 AM | americanbankingnews.com

Zevra Therapeutics Announces Open Label Extension Data Showing Sustained Long-Term Efficacy of MIPLYFFA for the Treatment of NPC Published in the Journal of Molecular Genetics ...

July 16 at 4:53 PM | finanznachrichten.de

Are You Looking for a Top Momentum Pick? Why Zevra Therapeutics (ZVRA) is a Great Choice

July 16 at 1:01 PM | zacks.com

5 Small Drug Stocks to Buy Amid Trump's New Tariff Threats

July 16 at 10:05 AM | zacks.com

Zevra Therapeutics Announces Open Label Extension Data Showing Sustained Long-Term Efficacy of MIPLYFFA for the Treatment of NPC Published in the Journal of Molecular Genetics and Metabolism

July 16 at 8:13 AM | globenewswire.com

Zevra Therapeutics Publishes Long-Term Efficacy and Safety Results for MIPLYFFA in Niemann-Pick Disease Type C

July 16 at 7:52 AM | quiverquant.comQ

Zevra Therapeutics (NASDAQ:ZVRA) Reaches New 12-Month High - Time to Buy?

July 16 at 6:20 AM | marketbeat.com

Q2 EPS Forecast for Zevra Therapeutics Raised by Analyst

July 16 at 6:02 AM | marketbeat.com

Wall Street Analysts Predict an 86.55% Upside in Zevra Therapeutics (ZVRA): Here's What You Should Know

July 15 at 12:40 PM | finance.yahoo.com

Wall Street Analysts Predict an 86.55% Upside in Zevra Therapeutics (ZVRA): Here's What You Should Know

July 15 at 10:56 AM | zacks.com

Here's Why 'Trend' Investors Would Love Betting on Zevra Therapeutics (ZVRA)

July 15 at 9:50 AM | zacks.com

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Given Average Rating of "Buy" by Brokerages

July 15 at 2:03 AM | americanbankingnews.com

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Receives Consensus Rating of "Buy" from Analysts

July 15 at 2:29 AM | marketbeat.com

Zevra Therapeutics (NASDAQ:ZVRA) Raised to Strong-Buy at Wall Street Zen

July 14, 2025 | americanbankingnews.com

Cantor Fitzgerald Issues Positive Outlook for ZVRA Earnings

July 14, 2025 | marketbeat.com

Zevra Therapeutics (NASDAQ:ZVRA) Price Target Raised to $29.00

July 13, 2025 | americanbankingnews.com

Zevra Therapeutics (NASDAQ:ZVRA) Upgraded to Strong-Buy at Wall Street Zen

July 12, 2025 | marketbeat.com

Zevra Therapeutics Announces MIPLYFFA® (arimoclomol) Featured in Presentations at the National Niemann Pick Disease Foundation Conference

July 11, 2025 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ZVRA, APGE, GLPG, and BHC Company Descriptions

Apogee Therapeutics NASDAQ:APGE

$39.31 +0.31 (+0.79%)

Closing price 04:00 PM Eastern

Extended Trading

$39.29 -0.02 (-0.06%)

As of 05:57 PM Eastern

Apogee Therapeutics, Inc., through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD. Its earlier-stage programs comprise APG990, an SQ extended half-life mAb for the treatment of AD; and APG222, an extended half-life SQ antibodies for AD. Apogee Therapeutics, Inc. was incorporated in 2022 and is headquartered in Waltham, Massachusetts.

Bausch Health Cos NYSE:BHC

$6.31 -0.17 (-2.62%)

Closing price 03:59 PM Eastern

Extended Trading

$6.32 +0.01 (+0.08%)

As of 06:06 PM Eastern

Bausch Health Companies Inc. operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health. The company operates through five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb. The Salix segment provides gastroenterology products in the United States. The International segment sells aesthetic medical devices, branded pharmaceuticals, generic pharmaceuticals, and OTC products internationally. The Solta Medical segment engages in the sale of aesthetic medical devices. The Diversified segment offers pharmaceutical products in the areas of neurology and certain other therapeutic classes; generic products; ortho dermatologic; and dentistry products in the United States. The Bausch + Lomb segment offers products in the areas of vision care, surgical, and ophthalmic pharmaceuticals products. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. is headquartered in Laval, Canada.

Galapagos NASDAQ:GLPG

$31.14 +0.48 (+1.57%)

Closing price 04:00 PM Eastern

Extended Trading

$31.14 0.00 (0.00%)

As of 04:04 PM Eastern

Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma. The company has collaboration agreements with Gilead Sciences, Inc.; and AbbVie S.à r.l. Galapagos NV was incorporated in 1999 and is headquartered in Mechelen, Belgium.

Zevra Therapeutics NASDAQ:ZVRA

$12.07 -0.59 (-4.66%)

Closing price 04:00 PM Eastern

Extended Trading

$11.98 -0.10 (-0.79%)

As of 06:05 PM Eastern

Zevra Therapeutics, Inc. discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy. The company is also developing Celiprolol, a prodrug product candidate that is under Phase 1/2 clinical trial for the treatment of vascular Ehlers Danlos syndrome. In addition, it offers AZSTARYS, a once-daily treatment for attention deficit hyperactivity disorder in patients aged six years and older; OLPRUVA to treat urea cycle disorders; and Arimoclomol for the treatment of niemann pick disease type C, an ultra-rare neurodegenerative lysosomal storage disorder. The company has collaboration and license agreement with Commave Therapeutics SA to develop, manufacture and commercialize the company's product candidates containing SDX and d-methylphenidate; and license agreement with Acer and Relief Therapeutics, Inc. to develop and commercialize rights for OLPRUVA. The company was formerly known as KemPharm, Inc. and changed its name to Zevra Therapeutics, Inc. in February 2023. Zevra Therapeutics, Inc. was incorporated in 2006 and is headquartered in Celebration, Florida.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time